Comorbidities affect clinical outcomes and costs in medicine. The hematopoietic cell transplantation (HCT)-specific comorbidity index (HCT-CI) predicts mortality risk after HCT. Its association with resource utilization (RU) is unknown. In this single-center, retrospective study, we examined the association of HCT-CI with RU (readmissions, length of hospital stay (LOS) and days out of hospital alive (DOHA)) in first 100 days (n = 328) and 1 year (n = 226) in allogeneic HCT patients from January 2010 to June 2014. Age, disease risk, conditioning and use of antithymocyte globulin were significantly different in the four groups with HCT-CI 0 to1 (n = 138), 2 (n = 56), 3 (n = 55) or ⩾ 4 (n = 79). Although the readmissions were higher in the first 100 days for patients with HCT-CI 40-1 (P = 0.03), they were not significantly different in patients over 1 year (P = 0.13). In the multivariable analysis, patients with HCT-CI score of 40 to 1 had increased LOS and fewer DOHA in both 100 days and 1 year after HCT. In this exploratory analysis, we found that HCT-CI 40 to 1 is associated with increased RU after allogeneic HCT. Recognizing predictors of RU can identify patients at risk of high utilization and help understand what drives health-care costs.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) is a commonly used treatment modality for many hematologic malignancies. It is an expensive medical technology with wide variation in reported costs. 1 Readmissions and length of hospital stay (LOS) as resource utilization (RU) parameters have been used as surrogates for costs. Readmissions after the index hospitalization for HCT are most commonly because of infection or GvHD and are associated with poor long-term outcomes. 2, 3 Whereas in HCT, these readmissions may not really be preventable, they likely have an economic impact, though it has not been examined extensively. On the other hand, LOS has been found to be a good proxy for costs with correlation coefficients ranging from 0.39 to 0.9. [4] [5] [6] A limitation of using LOS as the only indicator of RU is that patients who do not survive are not at risk for repeat hospital stay. Therefore, when examining the impact of a variable that may affect both mortality and LOS, days out of hospital alive (DOHA) as an end point can help capture the burden of both mortality and hospital stay. Recognizing predictors of RU can help identify patients at risk of high utilization and in understanding what drives health-care costs. This may have policy and payer implications.
Generally, pretransplant patient characteristics have not been found to be significant predictors of costs after HCT. 4, 7, 8 Other investigators have shown advanced disease risk and poor performance status to be associated with higher costs. [9] [10] [11] A recent CIBMTR (Center for International Blood and Marrow Transplantation Research) analysis has shown that pre-HCT depression is associated with increased mortality as well as longer hospital stay after HCT. 12 The HCT-comorbidity index (HCT-CI) predicts well the risks of mortality after HCT in all comers and especially in critically ill patients who received allogeneic transplantation admitted early to the intensive care unit. [13] [14] [15] However, whether the overall comorbidity index is associated with RU and costs after HCT is largely unknown. In nontransplantation settings, comorbidities have been associated with higher costs. [16] [17] [18] [19] Our study aimed to evaluate the association between the comorbidity index before HCT and RU specifically LOS and number of readmissions up to 1 year after HCT. We hypothesized that higher comorbidity would be associated with higher resource utilization.
PATIENTS AND METHODS Patients
The study protocol was approved by the institutional review board. Patients gave consent allowing their medical records to be used for research. A total of 328 consecutive patients who underwent a first allogeneic HCT from 27 January 2010 through 19 June 2014 at the Mayo Clinic Arizona were included. They were categorized into four groups with HCT-CI 0 to1 (n = 138), 2 (n = 56), 3 (n = 55) and ⩾ 4 (n = 79). All patients were admitted for the conditioning and stem cell infusion and discharge criteria were based on neutrophil engraftment, adequate oral intake and medical stability. They were readmitted to the hospital for management of complications such as febrile neutropenia/infections, GvHD, organ dysfunction, neuromuscular issues and so on. All patients were included for the 100-day analysis. Thirty-two patients died before 100 days. From the remaining patients, 70 were discharged home from the transplant center at day 100 and did not exclusively follow-up at our institution. Medical records were reviewed to confirm that the remaining patients continued to follow-up at Mayo Clinic Arizona beyond 100 days for a variable time. For the final cohort included in the long-term RU analysis, the follow-up was censored at the time of death, discharge from the transplant center to home (if between D100 and 1 year) or 1 year whichever was earlier.
The majority of the patients (68%) received reduced intensity regimens. GvHD prophylaxis was primarily with a calcineurin inhibitor (tacrolimus or cyclosporine) in combination with mycophenolate mofetil or methotrexate with few patients receiving antithymocyte globulin especially for mismatched transplants. Antimicrobial prophylaxis, blood product and nutritional support were provided per institutional guidelines.
Outcomes
Readmission was defined as ⩾ 1 hospitalization excluding the index hospitalization during a particular time interval. Number of readmissions, primary reason for readmission and LOS during the first year after HCT were determined by medical record review. To account for differential follow-up because of deaths, we also compared DOHA in the first 100 days and in 1 year after HCT among the four groups. DOHA, as a continuous end point of time tradeoff-adjusted survival, helps account for mortality as well as the number and duration of multiple hospitalizations, thus increasing the power to detect differences between groups. 20 
Statistical analysis
A descriptive analysis of the patient characteristics and outcomes for all patients for the first 100 days and for the subset of patients for 1-year post HCT was performed. The impact of HCT-CI on RU was also examined and stratified by age. Patient characteristics were compared by Kruskal-Wallis test for continuous variables and χ 2 test for categorical variables. Poisson models were used to compare LOS and DOHA among the four groups while controlling for significant patient (demographics, disease type and risk), and transplant-related (donor type, match and cell source) variables. Type of conditioning was highly correlated with HCT-CI. Hence, to avoid collinearity in the multivariable model, only HCT-CI is included. The follow-up period for the patients in the cohort for 1-year analysis differed, and it was incorporated in the model to account for the variation. The logarithm of the follow-up period was the offset term in the model. The percentage of DOHA was modeled by the Poisson regression. The ratio was reported as a measure of association between an explanatory variable and the outcome. A ratio of 41 indicated that relative to its reference group, a factor was associated with increased LOS and more DOHA. All statistical tests were two sided, and a P-value of o0.05 was considered to indicate statistical significance. Analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA).
RESULTS

Clinical characteristics and outcomes
Patient baseline characteristics are listed in Table 1 . Median age of the patients was 53 (range 18-76) years and 57% were male. In all, 56% patients had acute leukemia and 30% had high-risk disease based on the disease risk index as described by Armand et al.
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Gender distribution, diagnosis, donor type, degree of match and graft source were comparable among the four groups with HCT-CI 0 to 1, 2, 3 or ⩾ 4. Age, disease risk distribution and use of antithymocyte globulin was significantly different among the four groups based on HCT-CI. Specifically, with regard to the age, distribution of HCT-CI differed between age groups, with a higher proportion (74%) of patients ⩾ 65 years old as compared with 55% of those who were o65 years of age being in the HCT-CI groups of 2, 3 and ⩾ 4 (P = 0.009). Increased use of reduced intensity conditioning was present in groups with higher comorbidities. All baseline characteristics except donor type (proportion of unrelated donors in long-term cohort was higher, P = 0.02) were comparable between the patients who were discharged from the transplant center and were excluded from the long-term RU analysis (n = 70) and the long-term cohort (n = 226). Overall mortality was significantly higher with increasing comorbidities (26%, 32%, 42%, 46% in category of patients with HCT-CI 0 to 1, 2, 3, and ⩾ 4 respectively, P = 0.001), although relapse and GvHD rates were comparable. Abbreviations: ATG = antithymocyte globulin; HCT-CI = hematopoietic cell transplantation-specific comorbidity index; MA = myeloablative; MDS = myelodysplastic syndrome; MPD = myeloproliferative diseases; RIC = reduced intensity conditioning.
Short-term resource utilization Median LOS for the initial transplant hospitalization and all admissions in the first 100 days for the whole cohort was 25 days (interquartile range 23-30 days) and 29 days (interquartile range 24-41 days), respectively. It was significantly different among the four groups. When stratified by age, similar trends were noted in terms of higher RU in patients with HCT-CI of 2, 3 and ⩾ 4 as compared with patients with HCT-CI of 0 in both o65 and ⩾ 65 years of age group with overall longer LOS, and number of hospitalizations in the ⩾ 65 vs o 65 years of age group. Number and rate of readmissions (excluding primary transplant hospitalization) and proportion of days out of hospital for 100 days was also significantly different in all four groups (Table 2 ). On breaking down the subgroup of patients with HCT-CI ⩾ 4 into those with HCT-CI 4-5 vs 6+, the group with HCT-CI of 6+ showed much higher RU than any other category (data not shown). Fever/infection and GvHD were two main causes for readmissions in all four categories (Figure 1 ). Interestingly, neuromuscular issues including altered mental status/delirium, seizures, myositis/steroid myopathy and aseptic meningitis also emerged as an important cause for readmission in all four groups. In the multivariable Poisson regression analysis, HCT-Cl score of 2, 3 and ⩾ 4 was associated with increased LOS and fewer DOHA in patients as compared with those with HCT-Cl 0-1 (Table 3) .
Long-term resource utilization Rate and number of readmissions for the first 365 days was not significantly different among the four groups. Fever/infection remained the most common cause, though organ dysfunction and miscellaneous causes were more common than GvHD for readmission beyond 100 days ( Figure 2 ). Median LOS for the 226 patients who were included in the long-term RU cohort was 36 days (interquartile range 27-65 days). A higher LOS and a lower number of days out of hospital were observed in the three groups with HCT CI of 2, 3 and ⩾ 4 as compared with the group with HCT-CI of 0 to 1 (Table 2) . Again, the difference was even more marked when the group with HCT-CI of ⩾ 4 was broken down further into 4-5 and 6+ (data not shown). The observation of higher RU with increasing HCT-CI held true in the multivariable analysis also when the analysis for LOS and DOHA was adjusted for other patient and transplant-related variables (Table 3) .
DISCUSSION
Escalating health-care costs are a concern for patients, health-care providers, payers and policy makers. HCT is an expensive and resource-intensive modality of treatment for many hematological disorders. It generated the most rapid increase in total hospital costs from 2004 to 2007 with a growth rate of 84.9% and 1.3 billion dollars spent in 2007. 22 Whereas a quarter of this increase was because of an increase in mean cost of hospital stays, more than half was because of an increase in the number of hospital days. Economic analyses in HCT have described many patient and transplant characteristics associated with higher costs such as advanced disease, use of unrelated donors or alternative Comorbidities and resource utilization after HCT L Decook et al sources such as cord blood. 10, 23, 24 Post-HCT complications such as GvHD or sinusoidal obstruction syndrome have been shown to be major predictors of costs and RU after HCT. 4 Pre-HCT comorbidities have been shown to be associated not only with increased nonrelapse mortality but also higher risk of organ toxicity and severe GvHD. 14, 25 We explored whether this would translate into increasing RU after HCT in our retrospective study and found increasing HCT-Cl to be associated with higher RU. HCT-Cl scores of 2, 3 and ⩾ 4 were associated with increased LOS and fewer DOHA in patients compared with those with HCT-Cl 0-1 both during first 100 days and the first year after HCT. Although the readmissions were higher in the first 100 days for patients with HCT-CI 2, 3 and ⩾ 4, they were not significantly different when analyzed over 1 year. We also found that the association of RU with the comorbidity index is nonlinear, that is, the impact of increasing HCT-CI on readmissions or LOS was not additive with each point increase in the HCT-CI. It is possible that LOS was higher in the group of patients with HCT-CI of 2 as compared to the one with HCT-CI of 3.
A number of studies have shown that comorbidities have an impact on costs/health-care utilization. 16, 17, 19, 26, 27 Similar to the results of these studies, our study shows that HCT-CI can not only be used for prognostication of patient clinical outcomes but also predicting health-care RU and associated health-care costs of HCT including hospital LOS and readmissions. As comorbidities can influence both mortality and LOS, we also used DOHA as another end point. By combining mortality, LOS of the index hospital stay and the burden of subsequent hospital stays into a single end point, DOHA helps capture the overall burden. Our finding of DOHA being adversely affected by comorbidities is supported by studies by other investigators too, especially in cardiology literature. 28, 29 Readmissions have been recognized as a measure of quality of care as well as a significant contributor to health-care costs. Comorbidities have been shown to be predictors of higher readmissions. 30 Bejanyan et al. 31 have examined this issue in myeloablative allogeneic HCT population for 30-day readmissions and have shown that comorbidities, among other factors, influence the risk of readmission. We have been able to look at a more contemporary cohort of all conditioning regimens and a longer time frame to report similar findings for the first 100 days, though the difference was not significant for 1 year after HCT. For our analysis, because of small numbers, we combined both the myeloablative and reduced intensity regimens, though there is conflicting literature about whether conditioning intensity independently affects costs or health-care utilization. 5, [32] [33] [34] In our multivariable analysis, conditioning did not emerge as a significant predictor for short-or long-term resource utilization.
Our study has a few limitations. As a single-center study, the information provided by the study is somewhat influenced by the practice patterns at our center such as lack of outpatient transplants. However, being a center where a majority of our transplant recipients get longitudinal follow-up at our center itself, we were able to describe long-term costs up to 1 year. We also did not have actual cost data to be able to predict the difference in absolute costs with increasing HCT-CI or information about office visits and emergency room visits. However, as inpatient costs are a major proportion of overall HCT-related costs, LOS is a reasonable surrogate. It also makes the study results more generalizable as costs can be influenced by accounting methodologies but readmissions or LOS can be compared more easily among centers. Information about performance status and prior therapies was not available consistently and hence was not included in the model. Our study was not adequately powered to look at the contribution of individual organ comorbidities to medical resource utilization, and this is being examined in an ongoing project by two investigators on this study with a larger sample size and will also include outpatient costs/RU.
Despite these limitations, our study as an exploratory analysis is one of the first to demonstrate the value of the HCT-CI score in predicting RU after allogeneic HCT. As the field moves toward value-based care and tighter reimbursements, our analysis provides an important piece of information for patient selection for HCT by showing that patients with high comorbidity scores may not only have poor clinical outcomes but also could be more costly to the system. Larger multicenter studies are needed to validate these results and to better understand the contribution of comorbidities to the short-and long-term cost burden of this procedure. We acknowledge that the information that we provide is quite provocative, such as if there should be any cutoff for HCT-CI for taking a patient to transplant to get good clinical as well as economic outcomes. In such difficult cases, the guiding principle should remain as the ability to provide the treatment that is in the patient's best interest while considering its impact on medical, ethical and socioeconomic aspects and quality of life. 35 It remains to be seen whether multidisciplinary management of comorbidities and development of interventions that can help minimize the impact of comorbidities on clinical outcomes after HCT will be cost saving in the long term. In the meantime, a better understanding of the impact of comorbidities on the utilization of limited health-care resources can help guide the development of evidence-based payment models with reimbursements based on risk stratification for resource use and help improve quality of care.
